$1,318.00
This Market Spotlight report covers the Benign Prostatic Hyperplasia (BPH) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
Benign prostatic hyperplasia (BPH), also known as benign prostatic hypertrophy or benign prostatic obstruction, is a common problem in aging men. It refers to the nonmalignant enlargement of the prostate. The enlarged prostate gland presses against the urethra, and the bladder wall thickens. The bladder may eventually become weak, leading to urinary retention (inability to empty completely). Urinary retention and narrowing of the urethra are the causes of problems associated with BPH.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Watchful waiting
8 Pharmacological treatment
8 Surgical treatment
10 EPIDEMIOLOGY
14 MARKETED DRUGS
17 PIPELINE DRUGS
21 KEY UPCOMING EVENTS
22 KEY REGULATORY EVENTS
22 Nymox Fexapotide Odyssey Reaches FDA
23 PROBABILITY OF SUCCESS
24 REVENUE OPPORTUNITY
26 CLINICAL TRIAL LANDSCAPE
27 Sponsors by status
28 Sponsors by phase
30 BIBLIOGRAPHY
31 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of BPH, 2019–28
17 Figure 2: Overview of pipeline drugs for BPH in the US
17 Figure 3: Pipeline drugs for BPH, by company
17 Figure 4: Pipeline drugs for BPH, by drug type
18 Figure 5: Pipeline drugs for BPH, by classification
21 Figure 6: Key upcoming events in BPH
23 Figure 7: Probability of success in the urology pipeline
26 Figure 8: Clinical trials in BPH
26 Figure 9: Top 10 drugs for clinical trials in BPH
27 Figure 10: Top 10 companies for clinical trials in BPH
27 Figure 11: Trial locations in BPH
28 Figure 12: BPH trials status
29 Figure 13: BPH trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of BPH, 2019–28
13 Table 2: Prevalence proportions of BPH, by age
15 Table 3: Marketed drugs for BPH
19 Table 4: Pipeline drugs for BPH in the US
24 Table 5: Historical global sales, by drug ($m), 2017–21
25 Table 6: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!